Wolfgang Wick, MD, is Chairman of the Neurology Clinic at the University Hospital Heidelberg and Director for Neurooncology at the National Tumor Center at the University of Heidelberg, Germany. He is currently conducting multicenter phase I-III randomized trials for the Neurooncology Working Group (NOA) of the German Cancer Society, the European Organisation for Research and Treatment of Cancer (EORTC), the EU GAPVAC consortium, as well as a number of multicenter trials with the pharmaceutical industry. He is a steering committee member of the European Association for Neurooncology, as well as chairman of the EORTC Brain Tumor Group and the NOA. His main scientific interests include resistance mechanisms, immunotherapy, biomarkers, and radiosensitization. Professor Wick has written more than 250 publications in peer-reviewed journals, such as the Journal of Clinical Oncology, Lancet Oncology, Cancer Research, Nature, Nature Medicine, Neurology, Neuro Oncology, Annals of Neurology, The New England Journal of Medicine and Journal of Clinical Investigation.